Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Announce Stance on Copayments for OTC-like Drugs by Year-end
July 18, 2011
- Takeda Obtains Approval for Liovel Combination Tab
July 18, 2011
- Korosho Panel Fails to Form Consensus on HbA1c Data Reporting
July 18, 2011
- Onbrez Approved for COPD: Novartis
July 18, 2011
- Hepatitis B Settlements May Require General Tax Increase: Health Minister Hosokawa
July 18, 2011
- Antiepileptic Agent Rufinamide Approved in Canada: Eisai
July 18, 2011
- Over 70% of Women Aware of HPV Vaccine: Survey
July 18, 2011
- FDA Committee Recommends Withdrawal of Breast Cancer Indication from Avastin
July 18, 2011
- Bristol-Myers to Create Friendlier Work Environment for Women
July 18, 2011
- Council on Unapproved Drugs to Revise Assessment Criteria
July 18, 2011
- STATISTICS
July 18, 2011
- Sales of Ethical Drugs Up 7.5% in May: Crecon & Research Consulting
July 18, 2011
- Bayer Aiming for Top-10 Spot in Global Ethical Drug Market by 2015
July 18, 2011
- Pfizer Remains Top Global Drug Maker; Mergers Shake up Ranking
July 11, 2011
- Sanofi-aventis, Tohoku Univ. Sign Comprehensive Agreement for Life Science Research
July 11, 2011
- 24 APIs/34 Products Approved Following New Procedures
July 11, 2011
- Kyowa Hakko Kirin Starts Domestic PIII Trial for KW-3357
July 11, 2011
- Approvals for 3 Dasen-Like Drugs to Be Withdrawn
July 11, 2011
- AnGes MG Obtains Substance Patent for Novel Peptide AG-30 in Japan
July 11, 2011
- METI's Council Proposes Review of Patients' Drug Copayments
July 11, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…